Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of
mild to moderate Alzheimer disease. Subjects will be in the study for six months and will
receive subcutaneous injections once per week.